Work

Polatuzumab vedotin and obinutuzumab combination in octogenarians with B-cell non-Hodgkin lymphoma

Year: 2026

Type: article

Abstract: ABSTRACT: The outcomes of elderly patients with lymphoma are poor. There is scarcity of data on outcomes of chemotherapy-free regimens in patients older than 80 years with a B-cell lymphoma. We report three octogenarians with B-cell NHL and the efficacy and safety of a nonchemotherapy regimen using a lower dose of polatuzumab vedotin and anti-CD20 monoclonal antibody. No infusion-related adverse events were noted. No patient developed neutropenia. Peripheral neuropathy was grade 2 in all cases. Recurrent UTI were a concern in two patients. After a median of 6 cycles (range 1-6) of polatuzumab therapy, all three patients had achieved CR. One patient was lost to follow-up and succumbed to a multidrug-resistant gram-negative UTI. One patient relapsed at 13 months and other is doing well in remission at 15 months.

Source: Journal of Cancer Research and Therapeutics

DOI: 10.4103/jcrt.jcrt_1681_25

Authors: Avishek Chakravorty, Bhuvanesh N. Purohit, Anusha Mittal, Vivek Mohan, Rahul Naithani

Institutions: Paras Hospitals, Artemis Hospitals

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W7143378628

FWCI:

Cites: 10

Cited by:

Related to: 10